Shilpa targets three novel human-study entries by FY28

Shilpa targets three novel human-study entries by FY28: the Alveolus Bio and mAbTree programmes are expected to begin Phase I in 2HFY27, and Gate2Brain’s G2B-002 is targeted for first-in-human trials by FY28. Its fourth disclosed novel programme, recombinant human albumin, is planned to initiate Phase III trials in India and the European Union in 2HFY27.

What are Shilpa’s four novel biologic programmes?

Shilpa’s disclosed novel-biologics pipeline comprises an oncology monoclonal antibody, or mAb, programme with mAbTree; a live biotherapeutic product, or LBP, with Alveolus Bio; Gate2Brain’s G2B-002; and recombinant human albumin. The mAb programme is under development for oncology and is targeted for clinical trials in late FY27, while the Alveolus Bio programme is covered by a signed development-and-manufacturing contract.

The mAb asset has multiple potential indications and has received US Food and Drug Administration, or FDA, Orphan Drug Designation for essential thrombocythemia and polycythemia vera. Shilpa says its albumin programme has an approved global Phase III protocol from the Central Drugs Standard Control Organisation, or CDSCO, and targets an Investigational Medicinal Product Dossier, or IMPD, submission to the European Medicines Agency in 2HFY27.

When could Shilpa’s novel biologics reach human studies?

Shilpa expects the Alveolus Bio and mAbTree programmes to enter Phase I studies in 2HFY27, while G2B-002 is targeted for first-in-human trials by FY28. Phase I is the earliest clinical-study stage disclosed for the Alveolus Bio and mAbTree projects, whereas Shilpa identifies G2B-002’s planned milestone specifically as a first-in-human trial.

The timetable distinguishes the three early human-study programmes from albumin, which is moving into Phase III rather than its first clinical study. Within FY27, Shilpa gives both a late-FY27 clinical-trial target for the mAb asset and a 2HFY27 Phase I expectation for the mAbTree project, while G2B-002 is the named FY28 first-in-human milestone.

What role does Shilpa have in its partner programmes?

Shilpa has different stated roles across the three partnered assets. For Alveolus Bio, Shilpa has signed a development-and-manufacturing contract for the LBP; for Gate2Brain, it is a strategic shareholder and manufacturing partner for G2B-002; and for the mAbTree asset, its development programme is underway with a late-FY27 clinical-trial target. The presentation does not disclose an equity stake, commercialisation arrangement or manufacturing exclusivity for the mAbTree asset.

Shilpa’s Dharwad contract development and manufacturing organisation, or CDMO, disclosure adds two partnered novel biologic entity, or NBE, programmes for which it is the exclusive manufacturing partner and which are expected to enter human studies in 2HFY27. The presentation does not identify those two programmes or explicitly link them to Alveolus Bio or mAbTree, leaving the relationship between the named programmes and the exclusive-manufacturing projects unresolved.

How is Shilpa advancing recombinant human albumin?

Shilpa plans to initiate recombinant human albumin Phase III trials in India and the European Union in 2HFY27 and to file a US pre-Investigational New Drug, or pre-IND, submission in FY27. In Europe, Orion Corporation is Shilpa’s exclusive partner for distribution, marketing and sales of therapeutic recombinant human albumin, and Shilpa says it is entitled to certain development and regulatory milestone payments.

Albumin differs from the three earlier-stage partnered assets because Shilpa says it has invested in the product for more than eight years and has established a large-scale fermentation facility for manufacturing. The product is made in the yeast Pichia pastoris, Shilpa says all manufacturing raw materials are animal-origin-free, and the production technology is covered by patents in the US and Europe.

What manufacturing capacity supports Shilpa’s biologics pipeline?

Shilpa says its Dharwad CDMO is providing Phase I clinical supplies for three biologics programmes and expects three additional biologics CDMO programmes to enter human studies in FY28. It also reports five active NBE programmes for multiple partners, showing that the CDMO work extends beyond the four named novel-biologic programmes.

In antibody-drug conjugates, or ADCs, Shilpa expects its first ADC biosimilar to enter human studies in 1HFY28 and has initiated process development for a second ADC. Shilpa has commissioned an integrated good manufacturing practice, or GMP, ADC drug-substance facility in Dharwad, while reporting an increase in requests for quotations from global biotechnology companies without disclosing a number.

Conclusion

Shilpa’s disclosed novel-biologics pipeline combines two Phase I expectations in 2HFY27, a G2B-002 first-in-human target by FY28 and an albumin programme progressing to Phase III. Its roles range from development and manufacturing contractor to strategic shareholder and manufacturing partner, while the identity of two exclusive-manufacturing NBE projects remains undisclosed.

The next disclosed milestones are late-FY27 clinical-trial targeting for the mAb asset, Phase I expectations for Alveolus Bio and mAbTree in 2HFY27, and India and European Union Phase III initiation for albumin in 2HFY27. Shilpa also plans a US pre-IND filing for albumin in FY27, while G2B-002 and its first ADC biosimilar are targeted for human-study entries in FY28.